Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights to a biologic for the treatment of cold agglutinin disease, with milestone payments of up to $250 million.